QNCX Stock Price, Que Therapeutics, Inc. Quote, Chart

Market Summary

USD0.93-0.06

Market Closed

-6.06%

QNCX Stock Price

View Fullscreen

QNCX RSI Chart

QNCX Valuation

Market Cap

40.2M

Price/Earnings (Trailing)

-1.28

Price/Free Cashflow

-2.18

QNCX Price/Earnings (Trailing)

QNCX Profitability

Return on Equity

-36.89%

Return on Assets

-18.69%

Free Cashflow Yield

-45.91%

QNCX Fundamentals

QNCX Earnings

Earnings (TTM)

-31.4M

Earnings Growth (Yr)

-60.72%

Earnings Growth (Qtr)

-66.21%

Breaking Down QNCX Revenue

Last 7 days

-9.7%

Last 30 days

-11.4%

Last 90 days

-30.1%

How does QNCX drawdown profile look like?

QNCX Financial Health

Current Ratio

8.09

QNCX Investor Care

Shares Dilution (1Y)

19.12%

Diluted EPS (TTM)

-0.84

Tracking the Latest Insider Buys and Sells of Quince Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 16, 2024	thye dirk	acquired	190,791	0.793211	240,530	chief executive officer
Dec 14, 2023	lamond david	bought	23,532	1.04	22,627	-
Dec 13, 2023	lamond david	bought	22,627	1.00	22,627	-
Dec 12, 2023	lamond david	bought	22,773	1.02	22,327	-
Dec 12, 2023	lamond david	bought	300	1.00	300	-
Dec 07, 2023	lamond david	bought	19,314	1.01	19,123	-
Dec 06, 2023	lamond david	bought	19,505	1.02	19,123	-
Dec 05, 2023	lamond david	bought	19,314	1.01	19,123	-
Dec 01, 2023	lamond david	bought	13,515	0.94	14,378	-
Nov 30, 2023	lamond david	bought	12,940	0.9	14,378	-

Which funds bought or sold QNCX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	-	25.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	606	4,000	4,000	-%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	3.00	329	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	1.00	80.00	-%
Apr 16, 2024	SCHARF INVESTMENTS, LLC	unchanged	-	911	96,525	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.3	-43,599	1,020,390	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-50.00	-	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	57.79	40,737	125,728	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-4.38	-	-	-%

Are Funds Buying or Selling QNCX?

Are funds buying QNCX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own QNCX

No. of Funds

Unveiling Quince Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	7.5%	3,220,000	SC 13G/A
Feb 12, 2024	sofinnova partners sas	5.1%	2,178,150	SC 13G
Feb 07, 2024	bml investment partners, l.p.	0.0%	0	SC 13G/A
Dec 15, 2023	genextra s.p.a.	5.89%	2,525,950	SC 13G

Recent SEC filings of Quince Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	DEFA14A	DEFA14A
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	ARS	ARS
Apr 11, 2024	PRE 14A	PRE 14A
Apr 01, 2024	S-8	Employee Benefits Plan
Apr 01, 2024	10-K	Annual Report
Feb 15, 2024	8-K	Current Report
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	3	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Quince Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Quince Therapeutics, Inc. News

Latest updates

Quince Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	96.6%	168	85.00	89.00	93.00	104	110	118	116	133	147	161	175	189	205	219	231	124	133	143	71.00	73.00
Current Assets	-9.1%	77.00	85.00	89.00	92.00	94.00	98.00	99.00	96.00	112	119	136	150	138	143	152	169	106	124	134	64.00	73.00
Cash Equivalents	-4.1%	21.00	22.00	23.00	47.00	45.00	32.00	47.00	68.00	70.00	62.00	74.00	85.00	67.00	64.00	66.00	86.00	51.00	45.00	44.00	21.00	25.00
Net PPE	4580.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
Liabilities	95.4%	83.00	42.00	2.00	3.00	3.00	5.00	6.00	10.00	15.00	15.00	19.00	18.00	17.00	17.00	14.00	13.00	9.00	6.00	7.00	4.00	1.00
Current Liabilities	324.9%	10.00	2.00	2.00	3.00	3.00	5.00	6.00	10.00	14.00	14.00	19.00	18.00	17.00	16.00	14.00	13.00	9.00	6.00	7.00	4.00	1.00
Shareholder's Equity	2.3%	85.00	83.00	87.00	90.00	101	105	112	106	119	133	142	156	172	188	205	218	115	127	136	-	-
Retained Earnings	-2.8%	-319	-310	-305	-300	-288	-282	-274	-258	-236	-213	-191	-169	-146	-126	-104	-86.98	-69.81	-57.43	-47.57	-38.51	-32.83
Additional Paid-In Capital	2.1%	402	393	392	391	389	387	387	365	355	346	333	326	319	314	309	305	185	185	184	0.00	0.00
Shares Outstanding	18.2%	43.00	36.00	36.00	36.00	36.00	36.00	32.00	30.00	30.00	30.00	30.00	30.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	70.00	-	-	-	1,240	-	-	-	1,370	-	-	-	669	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-26.2%	-6,078	-4,818	-3,827	-3,569	-5,835	-6,697	-15,415	-16,091	-14,418	-17,342	-17,562	-13,610	-13,276	-12,371	-14,392	-10,779	-10,950	-8,796	-6,315	-7,216	-3,973
Share Based Compensation	-18.4%	1,086	1,331	1,322	1,481	1,632	694	5,052	9,240	8,493	7,619	6,750	6,991	4,959	4,158	3,398	1,955	577	912	377	190	108
Cashflow From Investing	48.3%	5,390	3,635	-20,323	5,540	18,666	-8,826	-5,251	13,413	20,919	766	5,624	31,643	15,826	10,371	-5,947	-72,681	17,704	9,222	-47,837	3,164	-
Cashflow From Financing	470.0%	57.00	10.00	26.00	50.00	-18.00	-5.00	108	622	990	4,705	672	441	45.00	90.00	889	117,852	-530	-	77,832	64.00	-10.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

QNCX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 9,447	$ 25,178
General and administrative	17,695	26,012
Goodwill impairment charge	0	825
Intangible asset impairment charge	5,900	0
Fair value adjustment for contingent consideration	1,578	0
Total operating expenses	34,620	52,015
Loss from operations	(34,620)	(52,015)
Fair value adjustment for long-term debt	(338)	0
Interest income	3,478	1,068
Other expense, net	(102)	(997)
Net loss before income tax benefit	(31,582)	(51,944)
Income tax benefit	197	284
Net loss	(31,385)	(51,660)
Other comprehensive income (loss):
Foreign currency translation adjustments	2,789	248
Unrealized gain (loss) on available-for-sale securities	547	(458)
Total comprehensive loss	$ (28,049)	$ (51,870)
Net loss per share - basic	$ (0.84)	$ (1.54)
Net loss per share - diluted	$ (0.84)	$ (1.54)
Weighted average shares of common stock outstanding - basic	37,237,149	33,496,534
Weighted average shares of common stock outstanding - diluted	37,237,149	33,496,534

QNCX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 20,752	$ 44,579
Short term investments	54,307	45,602
Prepaid expenses and other current assets	2,381	3,567
Total current assets	77,440	93,748
Assets held for sale	10	0
Property and equipment, net	234	393
Operating lease right-of-use assets	385	291
Long term investments	0	3,578
Goodwill	17,625	0
Intangible asset	63,672	5,900
Other assets	8,456	0
Equity investments in Lighthouse Pharmaceuticals, Inc.	78	0
Total assets	167,900	103,910
Current liabilities:
Accounts payable	2,033	570
Short term contingent consideration	4,103	0
Accrued expenses and other current liabilities	3,436	2,499
Total current liabilities	9,572	3,069
Long - term debt	13,429	0
Long-term operating lease liabilities	321	0
Long term contingent consideration	53,603	0
Deferred tax liabilities	5,304	248
Other long-term liabilities	587	0
Total liabilities	82,816	3,317
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 authorized (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 42,973,215 and 36,136,480 issued and outstanding as of December 31, 2023 and 2022, respectively	43	36
Additional paid in capital	401,638	389,105
Accumulated other comprehensive income (loss)	3,047	(289)
Accumulated deficit	(319,644)	(288,259)
Total stockholders’ equity	85,084	100,593
Total liabilities and stockholders’ equity	$ 167,900	$ 103,910

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

CEO	Dr. Dirk Thye M.D.
WEBSITE	quincetx.com
INDUSTRY	Biotechnology
EMPLOYEES	21

Quince Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Quince Therapeutics, Inc.? What does QNCX stand for in stocks?

QNCX is the stock ticker symbol of Quince Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quince Therapeutics, Inc. (QNCX)?

As of Thu May 02 2024, market cap of Quince Therapeutics, Inc. is 40.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QNCX stock?

You can check QNCX's fair value in chart for subscribers.

What is the fair value of QNCX stock?

You can check QNCX's fair value in chart for subscribers. The fair value of Quince Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quince Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QNCX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quince Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether QNCX is over valued or under valued. Whether Quince Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Quince Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QNCX.